Dhanvantri Jeevan Rekha Limited (531043) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Dhanvantri Jeevan Rekha Limited ₹17.46, price ₹22.55, upside -22.6%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Dhanvantri Jeevan Rekha Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 25, 2026.
How to read this chart
60‑month range ₹4.34 – ₹35.85 · fair‑value band ₹12.44 – ₹22.69 · the ₹22.55 price screens above the ₹17.46 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 25, 2026.
Follow Dhanvantri Jeevan Rekha in your weekly email
Every Wednesday you see whether Dhanvantri Jeevan Rekha is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Dhanvantri Jeevan Rekha Limited provides medical and health care services in India. The company operates the multi-specialty Dhanvantri hospital in Meerut.
Show more
Dhanvantri Jeevan Rekha Limited provides medical and health care services in India. The company operates the multi-specialty Dhanvantri hospital in Meerut. Its Dhanvantri Hospital offers diagnostic and therapeutic services, including cardiology, neurology, respiratory medicine, gastroenterology, gastro surgery, neuro surgery, orthopedic surgery, urology, oral and maxillofaccial surgery, oncology, otorhinolaryngology, pathology, rehabilitation program, and other diagnostic services. The company also operates intensive coronary care units and intensive care units. In addition, it offers services for various breast problems, such as mastalgias, mastopathies, breast lumps, and breast cancer, as well as screening for early breast cancers and training for self-examinations. Dhanvantri Jeevan Rekha Limited was founded in 1993 and is based in Meerut, India.
Stock analysis
Dhanvantri Jeevan Rekha Limited (531043) currently trades at ₹22.55, while our model-based Fair Value estimate is ₹17.46, 22.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹40.33 per share, and 10 of the 24 models we run sit above the ₹22.55 price.
Bear case: the Economic Profit group reads lowest at ₹10.46, and 14 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹12.44 (bear) to ₹22.69 (bull), the price of ₹22.55 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Dhanvantri Jeevan Rekha Limited reported revenue of ₹259M in FY2026 versus ₹168M in FY2022, a compound +11.4%/yr. Reported net income was ₹4.0M in FY2026, compounding −5.0%/yr from FY2022.
Key figures
Market cap ₹24.8M (≈ $257K) · P/E ratio 21.3 · P/S ratio 0.33 · EPS (TTM) ₹0.2810 · Net margin 1.5% · Return on assets (EBIT) 0.4% · Operating margin −9.6% · Revenue (TTM) ₹148M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 37% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −23%, 531043 screens richer than that median.
Fair Value models
Bear ₹12.44Fair Value ₹17.46Bull ₹22.69
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.1432 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+14.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.5%
Start year 2021 (pandemic). Over 10 years: +10.8% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−4.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−4.0%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−18% → 0%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−0.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about −4.2% a year for the price.
Compare Dhanvantri Jeevan Rekha Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 241 stocks
Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside−11.2% · Below median
Profitability
Return on assets0.0% · Bottom 25%
Net margin (TTM)−8.9% · Bottom 25%
Operating margin (TTM)−9.6% · Bottom 25%
Growth and dividend
Revenue growth−73.7% · Bottom 25%
Dividend yield (TTM)0.0% · Bottom 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Dhanvantri Jeevan Rekha Limited (531043) overvalued or undervalued?
As of Sep 25, 2026, our model estimates a fair value of ₹17.46 versus a price of ₹22.55, about −23% upside (overvalued).
What is the fair value of 531043?
Our model-based fair value for Dhanvantri Jeevan Rekha Limited is ₹17.46 (as of Sep 25, 2026), built from audited fundamentals. The current price: ₹22.55.
What is the quality score of 531043?
Dhanvantri Jeevan Rekha Limited has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dhanvantri Jeevan Rekha Limited (531043)?
Our model-based price target is the fair value of ₹17.46 (as of Sep 25, 2026) from 24 valuation models. Cautious scenario ₹12.44, optimistic scenario ₹22.69. It is a calculation from audited fundamentals, not an analyst target.
What is the Dhanvantri Jeevan Rekha Limited stock forecast for 2026?
Our models put fair value at ₹17.46, about −23% upside versus a price of ₹22.55 (overvalued). Cautious scenario ₹12.44, optimistic scenario ₹22.69. The calculation is refreshed regularly with new filings.
What is the revenue of Dhanvantri Jeevan Rekha Limited (531043)?
Dhanvantri Jeevan Rekha Limited reported trailing-twelve-month revenue of about ₹148M (latest available figure, as of Sep 25, 2026).
What growth is priced into Dhanvantri Jeevan Rekha Limited (531043)?
For today's price to be fair in a discounted-cash-flow model, Dhanvantri Jeevan Rekha Limited would have to grow free cash flow by -0.3 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +21.5 % per year. As of Sep 25, 2026.
What discount rate (WACC) does the fair value of 531043 use?
Our models discount Dhanvantri Jeevan Rekha Limited at 11.2 %: a base by market capitalisation (nano), damped by beta 0.62, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Dhanvantri Jeevan Rekha Limited that is -0.3 % per year a year over ten years, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Dhanvantri Jeevan Rekha Limited (531043) delivered so far?
Over the past 5 years revenue at Dhanvantri Jeevan Rekha Limited grew +21.5 % a year. The price currently implies -0.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Dhanvantri Jeevan Rekha Limited (531043) growing?
The median revenue growth in the sector is +7.6 % a year. That is the yardstick for the growth priced into Dhanvantri Jeevan Rekha Limited (-0.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Dhanvantri Jeevan Rekha Limited (531043)?
The free-cash-flow yield on the price is 9.48 %: that much free cash flow Dhanvantri Jeevan Rekha Limited produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Dhanvantri Jeevan Rekha Limited (531043)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dhanvantri Jeevan Rekha Limited it is ₹17.46 per share (as of Sep 25, 2026), against a price of ₹22.55. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Dhanvantri Jeevan Rekha Limited stock overvalued or undervalued in 2026?
As of Sep 25, 2026, 531043 trades above its calculated fair value: price ₹22.55, fair value ₹17.46, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 531043?
No. The price is what the market pays today (₹22.55); the fair value is what the company's own numbers justify (₹17.46). For Dhanvantri Jeevan Rekha Limited the two are ₹5.09 per share apart. That gap is exactly why we show both numbers side by side.
How much is Dhanvantri Jeevan Rekha Limited worth?
The market values Dhanvantri Jeevan Rekha Limited at about ₹24.8M (market capitalisation, as of Sep 25, 2026). Per share that is ₹22.55; our models calculate a fair value of ₹17.46 per share.
What do the bullish and bearish scenarios say about 531043?
Our models span a range for Dhanvantri Jeevan Rekha Limited: cautious scenario ₹12.44, base ₹17.46, optimistic ₹22.69 per share (as of Sep 25, 2026, price ₹22.55). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 531043?
Dhanvantri Jeevan Rekha Limited trades at a price-to-earnings ratio of 21.3 (as of Sep 25, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹17.46 is built from several models across several years.
How far is 531043 from its 52-week high?
Dhanvantri Jeevan Rekha Limited trades at ₹22.55, about 37% below its 52-week high of ₹35.85 and 15% above the low of ₹19.53 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹17.46 is for.
Which stocks are comparable to Dhanvantri Jeevan Rekha Limited?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dhanvantri Jeevan Rekha Limited stock attractive at the current price?
The data as of Sep 25, 2026: price ₹22.55, calculated fair value ₹17.46 (−23%), Quality Score 58/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 531043 calculated?
We run Dhanvantri Jeevan Rekha Limited through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹17.46, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Dhanvantri Jeevan Rekha Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dhanvantri Jeevan Rekha Limited (531043)?
The closing price on Oct 1, 2026 was ₹22.55. Our model-based fair value is ₹17.46, about −23% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dhanvantri Jeevan Rekha Limited right now?
Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹12.44 to ₹22.69) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Dhanvantri Jeevan Rekha Limited
How large is the market capitalisation of Dhanvantri Jeevan Rekha Limited (531043)?
The market capitalisation of Dhanvantri Jeevan Rekha Limited is ₹24.8M (≈ $257K). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dhanvantri Jeevan Rekha Limited (531043)?
The price-to-sales ratio of Dhanvantri Jeevan Rekha Limited is 0.33 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Dhanvantri Jeevan Rekha Limited (531043)?
Earnings per share at Dhanvantri Jeevan Rekha Limited are ₹0.2810 (price ÷ EPS = P/E 21.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Dhanvantri Jeevan Rekha Limited (531043)?
The net margin of Dhanvantri Jeevan Rekha Limited is 1.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Dhanvantri Jeevan Rekha Limited (531043)?
On an EBIT basis the return on assets of Dhanvantri Jeevan Rekha Limited is 0.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dhanvantri Jeevan Rekha Limited (531043)?
The operating margin of Dhanvantri Jeevan Rekha Limited is −9.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dhanvantri Jeevan Rekha Limited (531043)?
Revenue at Dhanvantri Jeevan Rekha Limited is growing −73.7% versus a year earlier (3y avg +13.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Dhanvantri Jeevan Rekha Limited (531043)?
Earnings per share at Dhanvantri Jeevan Rekha Limited are growing −16.7% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Dhanvantri Jeevan Rekha Limited in the live analysis
One click puts Dhanvantri Jeevan Rekha Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
